{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-052600","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.383492+00:00","generated_at":"2026-05-28T21:35:43.353694+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable","bullets":["No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.","Low infectivity of H3N2 challenge strain made virology data uninterpretable; enrollment to be extended.","Company plans to submit protocol amendment to UK MHRA to extend enrollment and ensure adequate infection rates.","CC-42344 showed favorable safety/tolerability, but low infection rate hindered antiviral data analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-052600","json":"https://secwatch.observer/filing/0001493152-24-052600.json","markdown":"https://secwatch.observer/filing/0001493152-24-052600.md","text":"https://secwatch.observer/filing/0001493152-24-052600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/0001493152-24-052600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:35:43.353694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}